Therefore, most of the pharmaceutical research on inhibiting LPA signaling has focused on ATX inhibitor development for both cancer and inflammatory conditions such as pulmonary idiopathic fibrosis [37]. This evidence concerns the gene ENPP2 and pulmonary fibrosis.